Receptors for ligand-dependent transcriptional regulation

Patent metadata

Field	Value
Publication number	US-11897932-B2
Application number	US-202117217635-A
Country	US
Kind code	B2
Filing date	Mar 30, 2021
Priority date	Sep 24, 2019
Publication date	Feb 13, 2024
Grant date	Feb 13, 2024

Abstract

The present disclosure generally relates to, among other things, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. Particularly, the new receptors, even though derived from Notch, do not require the Notch negative regulatory regions previously believed to be essential for the functioning of the receptors. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions or diseases, such as cancers.

First claim

What is claimed is:

1. A chimeric polypeptide comprising, from N-terminus to C-terminus:
a) an extracellular ligand-binding domain comprising a single chain variable fragment (scFv) having a binding affinity for a selected ligand;
b) a linking polypeptide comprising the sequence of SEQ ID NO: 19;
c) a transmembrane domain from a human Notch receptor comprising one or more ligand-inducible proteolytic cleavage sites; and
d) an intracellular domain comprising a transcriptional regulator, wherein binding of the selected ligand to the extracellular ligand-binding domain induces cleavage at the ligand-inducible proteolytic cleavage site disposed between the transcriptional regulator and the linking polypeptide,
and wherein the chimeric polypeptide does not comprise a LIN-12-Notch repeat (LNR) nor a heterodimerization domain (HD) of a Notch receptor.

2. The chimeric polypeptide of claim 1 , wherein the transmembrane domain further comprises a stop-transfer-sequence.

3. The chimeric polypeptide of claim 1 , wherein the scFv is capable of binding to a ligand on the surface of a cell.

4. The chimeric polypeptide of claim 3 , wherein the cell is a human cell.

5. The chimeric polypeptide of claim 3 , wherein the cell is a tumor cell.

6. The chimeric polypeptide of claim 1 , wherein the ligand comprises a protein or a carbohydrate.

7. The chimeric polypeptide of claim 1 , wherein the ligand is selected from the group consisting of CD19, CD59, CD66, CD73, CD80 (B7.1), CD86 (B7.2), CD94, CD134, CD140 (PDGFR4), CD152, CD154, CD158, CD178, CD181 (CXCR1), CD182 (CXCR2), CD183 (CXCR3), CD246, CD273 (PD-L2), CD274 (PD-L1), CD295, CD340 (HER2), FGFR2, CEA, AFP, CA125, MUC-1, MAGE, alkaline phosphatase, placental-like 2 (ALPPL2), green fluorescent protein (GFP), enhanced green fluorescent Protein (eGFP), and signal regulatory protein α (SIRPα).

8. The chimeric polypeptide of claim 1 , wherein the ligand is selected from cell surface receptors, adhesion proteins, integrins, mucins, lectins, tumor associated antigens, and tumor-specific antigens.

9. The chimeric polypeptide of claim 1 , wherein the ligand is a tumor-associated antigen selected from the group consisting of CD19, B7H3 (CD276), BCMA, CD123, CD171, CD179a, CD20, CD213A2, CD22, CD24, CD246, CD272, CD30, CD33, CD38, CD44v6, CD46, CD71, CD97, CEA, CLDN6, CLECL1, CS-1, EGFR, EGFRvIII, ELF2M, EpCAM, EphA2, Ephrin B2, FAP, FLT3, GD2, GD3, GM3, GPRC5D, HER2 (ERBB2/neu), IGLL1, IL-11Ra, KIT (CD117), MUC1, NCAM, PAP, PDGFR-beta, PRSS21, PSCA, PSMA, ROR1, SSEA-4, TAG72, TEM1/CD248, TEM7R, TSHR, VEGFR2, BCMA (CD269), ALPPL2, ALPI, citrullinated vimentin, cMet, and Axl.

10. The chimeric polypeptide of claim 1 , wherein the ligand-inducible proteolytic cleavage site is a gamma-secretase cleavage site.

11. The chimeric polypeptide of claim 1 , wherein the intracellular domain comprises a nuclear localization sequence and a transcriptional regulator sequence selected from the group consisting of Ga14-VP16, Ga14-VP64, tetR-VP64, ZFHD1-VP64, Ga14-KRAB, and HAP1-VP16.

12. The chimeric polypeptide of claim 1 , further comprising a signal sequence, a detectable label, a tumor-specific cleavage site, a disease-specific cleavage site, and combinations thereof.

13. A recombinant cell comprising: a chimeric polypeptide according to claim 1 .

14. The chimeric polypeptide of claim 1 , wherein the transmembrane domain is from human Notch 1 receptor.

15. The chimeric polypeptide of claim 1 , wherein the transmembrane domain is from human Notch 2 receptor.

16. The chimeric polypeptide of claim 1 , wherein the transmembrane domain is from human Notch 3 receptor.

17. The chimeric polypeptide of claim 1 , wherein the transmembrane domain is from human Notch 4 receptor.

Assignees

• Univ California

Inventors

• Roybal Kole T
• Liu Raymond
• Zhu Iowis

Classifications

• A61K40/4202

  Receptors, cell surface antigens or cell surface determinants · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• C12N5/0636

  T lymphocytes · CPC title

• C07K14/705 Primary

  Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} · CPC title